title: Risk factors for failure of Helicobacter pylori therapy--results of an individual data analysis of 2751 patients.
abstract: OBJECTIVE
  To study risk factors for failure of Helicobacter pylori eradication treatment.
  
  
  METHODS
  Individual data from 2751 patients included in 11 multicentre clinical trials carried out in France and using a triple therapy, were gathered in a unique database. The 27 treatment regimens were regrouped into four categories.
  
  
  RESULTS
  The global failure rate was 25.8% [95% CI: 24-27]. There was a difference in failure rate between duodenal ulcer patients and non-ulcer dyspeptic patients, 21.9% and 33.7%, respectively (P < 10(-6)). In a random-effect model, the risk factors identified for eradication failure in duodenal ulcer patients (n = 1400) were: to be a smoker, and to have received the group 4 treatment, while to receive a 10 day treatment vs. 7 days protected from failure. In non-ulcer dyspeptic patients (n = 913), the group 2 treatment was associated with failure. In both groups, age over 60 was associated with successful H. pylori eradication. There were less strains resistant to clarithromycin in duodenal ulcer patients than in non-ulcer dyspeptic patients. Clarithromycin resistance predicted failure almost perfectly.
  
  
  CONCLUSIONS
  Duodenal ulcer and non-ulcer dyspeptic patients should be managed differently in medical practice and considered independently in eradication trials.
authors.affiliation: Unité d'Epidémiologie des Maladies Digestives, Laboratoire de Bactériologie, Université Victor Segalen Bordeaux 2, 146 rue Léo Saignat, 33076 Bordeaux Cedex, France.
authors.forename: N
authors.initials: N
authors.lastname: Broutet
authors.forename: S
authors.initials: S
authors.lastname: Tchamgoué
authors.forename: E
authors.initials: E
authors.lastname: Pereira
authors.forename: H
authors.initials: H
authors.lastname: Lamouliatte
authors.forename: R
authors.initials: R
authors.lastname: Salamon
authors.forename: F
authors.initials: F
authors.lastname: Mégraud
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D017291:Clarithromycin / Q000627:therapeutic use*; D004351:Drug Resistance; D004381:Duodenal Ulcer / Q000382:microbiology; D004415:Dyspepsia / Q000382:microbiology; D005260:Female; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D015999:Multivariate Analysis; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D017291:Clarithromycin